Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 1/2 1

Status

Recruiting 9Active not recruiting 8Terminated 6Not yet recruiting 2Withdrawn 1Completed 1

Sponsor Class

OTHER 6INDUSTRY 3

Study Type

Interventional 5Observational 1

Sponsor

Cancer Type

Plasma cell 5Lymphoid 1

Conditions

Multiple Myeloma 5Plasmablastic Lymphoma 1Corneal Diseases 1

Interventions

Cyclophosphamide 241Radiotherapy 217Gemcitabine 187Cisplatin 185Carboplatin 182Docetaxel 166Bevacizumab 166Paclitaxel 144Capecitabine 142Rituximab 141pembrolizumab 140Nivolumab 126Oxaliplatin 124Dexamethasone 122Fluorouracil 113fludarabine 104Radiosurgery 101Doxorubicin 99fludarabine phosphate 97Irinotecan 96Etoposide 95Lenalidomide 93Cytarabine 92Magnetic Resonance Spectroscopy 90Radiation 89Filgrastim 89Leucovorin 88Bortezomib 86Cetuximab 80Pemetrexed 79

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Terminated × OTHER × belantamab mafodotin × Clear all
NCT04676360 2026-03-13

Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma

Massachusetts General Hospital

Phase 2 Terminated
10 enrolled 11 charts
Lymphoid

Plasmablastic Lymphoma

NCT05065047 2025-11-12

Belantamab Mafadotin Maintenance Therapy After Salvage Autologous Hematopoietic Cell Transplantation in Patients With Relapse Refractory Multiple Myeloma

M.D. Anderson Cancer Center

Phase 1 Terminated
6 enrolled
Plasma cell

Multiple Myeloma

NCT04892264 2025-05-18

Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma

Mayo Clinic

Phase 1 Terminated
5 enrolled
Plasma cell

Multiple Myeloma

NCT05833737 2025-05-08

Corneal Findings in Patients Treated With Belantamab Mafodotin

Medical University of Vienna

Terminated
12 enrolled
Plasma cell

Corneal Diseases, Multiple Myeloma

NCT04896658 2025-04-03

Belantamab Mafodotin, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma

University of Maryland, Baltimore

Phase 1/2 Terminated
10 enrolled 14 charts
Plasma cell

Multiple Myeloma

NCT05117008 2025-01-28

EMBRACE

Medical College of Wisconsin

Phase 2 Terminated
1 enrolled 5 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡